The LRIG3 protein is part of the LRIG family, which is characterized by containing leucine-rich repeat (LRR) and immunoglobulin (Ig)-like domains, features that are often involved in protein-protein interactions and can play roles in signaling pathways. To develop LRIG3 activators, a thorough understanding of the protein's structure and function would be essential. Researchers would first need to elucidate the protein's role in cellular processes and its interaction with other cellular components. Advanced techniques such as X-ray crystallography or cryo-electron microscopy might be used to determine the three-dimensional structure of LRIG3, revealing potential binding sites for activator molecules. Alongside structural studies, functional assays would be crucial to understand the consequences of LRIG3 activation within cells, providing a baseline against which the activity of potential activators could be measured.
Once potential binding sites have been identified, the search for LRIG3 activators would involve screening compound libraries to find molecules that can bind to and activate LRIG3. This process might use high-throughput screening assays to rapidly test thousands of compounds for their ability to modulate the protein's activity. Hits from these screens would represent initial candidates for LRIG3 activators and would be subjected to further testing and refinement. Subsequent optimization stages would involve chemical modifications to these hits to improve their selectivity, potency, and cellular uptake, ensuring that the molecules are effective at activating LRIG3 in the cellular context. This process would likely be iterative, with each round of modification informed by structure-activity relationship (SAR) studies that assess how changes to the compounds' structures affect their ability to activate LRIG3. Ultimately, the development of a class of LRIG3 activators would expand the set of molecular tools available for probing the role of this protein in cellular processes and could provide important insights into the function of LRIG3 within the biological context.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $45.00 $130.00 $480.00 $4450.00 | 74 | |
As a cAMP analog, db-cAMP can activate PKA and potentially influence transcription factors that upregulate LRIG3 expression. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $65.00 $319.00 $575.00 $998.00 | 28 | |
Retinoic acid is involved in growth and differentiation; it could affect transcription factors that regulate LRIG3. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $42.00 $72.00 $124.00 $238.00 $520.00 $1234.00 | 11 | |
EGCG has been shown to modify growth factor signaling, which could theoretically increase LRIG3 expression as a feedback mechanism. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium influences Wnt signaling pathway, which might lead to changes in gene expression including potentially upregulating LRIG3. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin activates adenylate cyclase, increasing cAMP levels and potentially influencing LRIG3 expression through PKA signaling pathways. | ||||||
D,L-Sulforaphane | 4478-93-7 | sc-207495A sc-207495B sc-207495C sc-207495 sc-207495E sc-207495D | 5 mg 10 mg 25 mg 1 g 10 g 250 mg | $150.00 $286.00 $479.00 $1299.00 $8299.00 $915.00 | 22 | |
Sulforaphane can activate Nrf2, a transcription factor that may indirectly upregulate growth factor-related genes like LRIG3. | ||||||
Cholecalciferol | 67-97-0 | sc-205630 sc-205630A sc-205630B | 1 g 5 g 10 g | $70.00 $160.00 $290.00 | 2 | |
Vitamin D3 through its active metabolite can modulate gene expression, potentially affecting genes like LRIG3. | ||||||
Metformin | 657-24-9 | sc-507370 | 10 mg | $77.00 | 2 | |
As an AMPK activator, metformin might influence cellular metabolism and growth, potentially impacting LRIG3 expression. | ||||||
Pioglitazone | 111025-46-8 | sc-202289 sc-202289A | 1 mg 5 mg | $54.00 $123.00 | 13 | |
A PPARγ agonist that may affect transcription of genes involved in growth factor signaling, potentially including LRIG3. | ||||||
Dimethyloxaloylglycine (DMOG) | 89464-63-1 | sc-200755 sc-200755A sc-200755B sc-200755C | 10 mg 50 mg 100 mg 500 mg | $82.00 $295.00 $367.00 $764.00 | 25 | |
DMOG inhibits prolyl hydroxylase, stabilizing HIF-1α and possibly affecting genes regulated by hypoxic responses, which may include LRIG3. | ||||||